(Total Views: 348)
Posted On: 09/09/2019 8:35:38 AM
Post# of 149263
So what will our news be for september 12th?
I’m betting on a Bayer partnership for metastatic colorectal cancer.
Only recently (july 18th) Bayer, Bristol Meyers Squibb and Ono Pharma released partnering news for a combination therapy for metastatic colorectal cancer.
(https://news.bms.com/press-release/partnering-news/bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-clinical-colla)
This is what Scott Z. Fields, M.D., senior vice president and head of Oncology Development at Bayer's Pharmaceuticals Division stated:
“Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology (I-O) treatments for certain subsets of CRC, around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. Thus, the need for additional treatment options including combination approaches remains high”
Regorafenib (Bayer) and nivolumab (BMS/OP) both have SAE’s thus it’s no surprise Bayer would like to partner with Cydy given Leronlimabs safety profile. And like SF stated: the need for additional treatment options including combination approaches remains high.
Yes, I’m somehow expect an agreement with Bayer to be announced.
I’m betting on a Bayer partnership for metastatic colorectal cancer.
Only recently (july 18th) Bayer, Bristol Meyers Squibb and Ono Pharma released partnering news for a combination therapy for metastatic colorectal cancer.
(https://news.bms.com/press-release/partnering-news/bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-clinical-colla)
This is what Scott Z. Fields, M.D., senior vice president and head of Oncology Development at Bayer's Pharmaceuticals Division stated:
“Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology (I-O) treatments for certain subsets of CRC, around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. Thus, the need for additional treatment options including combination approaches remains high”
Regorafenib (Bayer) and nivolumab (BMS/OP) both have SAE’s thus it’s no surprise Bayer would like to partner with Cydy given Leronlimabs safety profile. And like SF stated: the need for additional treatment options including combination approaches remains high.
Yes, I’m somehow expect an agreement with Bayer to be announced.
(1)
(0)Scroll down for more posts ▼
